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Disappointing Durable Remission Rates in Complex Crohn’s
Disease Fistula
Ilse Molendijk, MD,* Veerle J. A. A. Nuij, MSc,† Andrea E. van der Meulen-de Jong, MD, PhD,*
and C. Janneke van der Woude, MD, PhD†
Background: Despite potent drugs and surgical techniques, the treatment of perianal fistulizing Crohn’s disease (CD) remains challenging. We
assessed treatment strategies for perianal fistulizing CD and their effect on remission, response, and relapse.
Methods: Patients with perianal fistulizing CD visiting the Erasmus MC between January 1, 1980 and January 1, 2000 were identified. Demographics,
fistula characteristics, and received treatments aimed at the outcome of these strategies were noted.
Results: In total, 232 patients were identified (98 male; 42.2%). Median follow-up was 10.0 years (range, 0.5–37.5 yr). Complex fistulas were present in
78.0%. Medical treatment (antibiotics, steroids, immunosuppressants, and anti-tumor necrosis factor) commenced in 79.7% of the patients and in 53.2%,
surgery (colectomy, fistulectomy, stoma, and rectum amputation) was performed. Simple fistulas healed more often than complex fistulas (88.2% versus
64.6%; P, 0.001). Rectum involvement was not associated with a lower remission rate, and anti-tumor necrosis factor therapy did not increase complete
fistula healing rates in simple and complex fistula. Initially, healed fistulas recurred in 26.7% in case of simple fistulas and in 41.9% in case of complex
fistulas (P ¼ 0.051). Only 37.0% of the complex fistulas were in remission at the end of follow-up compared with 66.7% of the simple fistulas (P ,
0.001).
Conclusions: Only the minority of CD complex perianal fistulas were in remission after conventional treatment strategies after a median follow-up of
10 years. Simple fistulas were more likely to heal than complex fistulas, and less of these healed fistulas relapsed. However, more than 3 quarters of the
patients had complex perianal fistulas.
(Inflamm Bowel Dis 2014;20:2022–2028)
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T he development of perianal fistulas along with rectal pain andcontinuous drainage is a common complication of Crohn’s
disease (CD).1–5 The cumulative incidence of perianal fistulas was
estimated at 23% to 26% after 20 years of CD.6,7 In almost half of
the patients, perianal fistulas were diagnosed before or at the time
of the diagnosis of CD.6,7 Patients with active rectal disease have
more frequently perianal fistulas compared with patients with
isolated ileal disease.6–12 Furthermore, male gender, age at diag-
nosis of CD, and smoking are associated with the development of
perianal fistulas, although data are conflicting.6–8,10,12–15
Although a range of medical and surgical options is
available nowadays, the treatment of perianal fistulas remains
challenging. Current medical strategies include antibiotics
(ciprofloxacin and metronidazole),16–18 immunosuppressants,
such as azathioprine and 6-mercaptopurine,19,20 and the anti-
tumor necrosis factors (TNFs), such as infliximab, adalimumab,
and certolizumab pegol.21–25 Symptomatic simple fistulas can be
treated with a noncutting seton or fistulotomy. Active luminal
disease should be treated before surgical treatment.26 In case of
complex fistulas, drainage is achieved by placement of a noncut-
ting seton to reduce the risk of perianal abscess formation prefer-
ably in combination with anti-TNF and antibiotics. In the ADAFI
trial,27 patients with perianal fistulas treated with the anti-TNF
agent, adalimumab along with ciprofloxacin for 12 weeks, had
a significant higher response and remission rate than patients
treated with adalimumab alone.
With this study, we aimed to assess in a single center
retrospective cohort different treatment strategies for perianal
fistulizing CD and the effect of these treatments on the response,
remission, and relapse rate.
MATERIALS AND METHODS
Patients
Patients treated for perianal fistulizing CD who visited the
Erasmus MC University Hospital between January 1, 1980 and the
January 1, 2000 were identified through a search in the hospital
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diagnosis system. This search was performed as follows: First, all
letters from patients were identified by the term fistulizing disease.
Second, letters containing the words CD were obtained, and
finally, these letters were combined with the obtained letters from
the first search. The patient charts obtained from the latter search
were reviewed independently by 2 investigators. Patients with the
first diagnosis of perianal fistulizing disease at or after the
diagnosis of CD and with a follow-up for at least 6 months were
included. Follow-up time was from the onset of fistulizing CD
until the date of last follow-up or January 1, 2010.
Data Extraction
Demographic information, date of diagnosis CD, disease
localization, time between the diagnosis of CD and the develop-
ment of perianal fistulas, fistula character, medical and surgical
treatment received for perianal fistulas, and subsequently
response, remission, and relapse were extracted from all charts.
The diagnosis of CD and the extent of the disease were
confirmed, according to the Lennard-Jones28 criteria. The locali-
zation of the disease was classified into 7 groups: upper gastro-
intestinal tract, small bowel, large bowel, ileocecal, large and
small bowel, perianal, and entire gastrointestinal tract. In addition,
involvement of the rectum was determined.
The diagnosis of perianal fistulizing disease was based on
endoscopic, radiographic, or clinical evidence. Fistula character
was classified as “simple” or “complex” following the criteria of
Sandborn et al.29 The medical therapies received as treatment for
perianal fistulas were divided in antibiotics, corticosteroids, immu-
nosuppressants, and anti-TNFs. Furthermore, the patient’s history
of colon resection, fistulectomy, placement of a stoma, and rectum
amputation was noted. The response to medical and/or surgical
treatment was defined as a decrease of discharge, pain, and bleed-
ing from the fistula tract, and remission was defined as the absence
of an external opening without discharge on history and physical
examination. Relapse was defined as recurred discharge on history
and physical examination with reopening of the previous external
opening and/or formation of new perianal fistulas after initial remis-
sion. Worsening of the disease after the start of medical and/or
surgical treatment with or without an initial response was defined
as an increase of discharge, pain, and bleeding from the fistula tract.
Outcome Assessment
The primary objective was to assess the remission rate of
CD perianal fistulas after medical and/or surgical treatment.
Secondary parameters included response and relapse.
Statistical Analysis
The data were presented in percentages, medians, and
ranges. The Mann–Whitney U test was used to compare nonpara-
metric data sets, and the Fisher’s exact test was used to determine
whether a significant association existed between 2 data sets.
All statistical analyses were performed using the SPSS statistical




In the final search, 436 patients who visited the Erasmus
MC University Hospital between January 1, 1980 and January
1, 2000 from whom letters contained the terms “fistulizing dis-
ease” and “CD” were identified (Table 1, Fig. 2). Of these
patients, 204 were excluded because of the following reasons:
CD was not confirmed endoscopically, histologically, or radio-
logically (13.1%); the diagnosis of fistulizing disease was
before the diagnosis of CD (10.1%); fistulizing disease was
not diagnosed (1.4%); only enterocutaneous or enteroenteric
fistulas (6.0%), rectovaginal fistulas (2.8%), or pouch–vaginal
fistulas (0.7%) were confirmed; the fistulas were related to
a complicated surgery (0.9%); the follow-up period after the
diagnosis of perianal fistulas was ,6 months (10.1%); and no
information on complexity of perianal fistulas was documented
(1.8%). A total of 232 patients (98 men [42.2%]) were included
for further evaluation.
The median age at diagnosis of CD was 22.8 years (range,
4.0–68.7 yr). CD localization is shown in Table 1. The median
age at diagnosis of fistulizing disease was 29.4 years (range, 9.1–
77.3 yr). In total, 66 patients (28.4%) developed fistulas within 6
TABLE 1. Demographic Characteristics of the Perianal
Fistulizing CD Cohort
Perianal Fistulizing
CD (n ¼ 232)
Male, n (%) 98 (42.2)
CD characteristics
Age at diagnosis, median (range), yr 22.8 (4.0–68.7)
Localization, n (%)
Upper GI 11 (4.7)
Small bowel 16 (6.9)
Ileocecal 35 (15.1)
Large bowel 88 (37.9)
Small + large bowel 67 (28.9)
Whole GI tract 2 (0.9)
Isolated perianal disease 13 (5.6)
Rectal involvement, n (%) 96 (41.4)
Perianal fistula characteristics
Diagnosis after 1999, n (%) 129 (55.6)
Age at diagnosis, median (range), yr 29.4 (9.1–77.3)
Diagnosis within 6 mo after diagnosis of CD,
n (%)
66 (28.4)
Time to diagnosis if .6 mo after diagnosis of
CD, median (range), yr
7.0 (0.7–38.0)
Follow-up time, median (range), yr 10.0 (0.5–37.5)
Complex, n (%) 181 (78.0)
GI, gastrointestinal tract.
Inflamm Bowel Dis  Volume 20, Number 11, November 2014 Complex Crohn’s Disease Fistula
www.ibdjournal.org | 2023
months after the onset of CD and in 78.9%, perianal fistulas
developed within 10 years after the diagnosis of CD with a median
duration of 7.0 years (range, 0.7–38.0 yr) (Fig. 1). Median follow-
up time from fistula diagnosis was 10.0 years (range, 0.5–37.5 yr).
Patients with a complex fistula (78.0%) did not significantly differ
from patients with a simple fistula (22.0%) about sex, age at
diagnosis of (fistulizing) CD, time of diagnosis (before or after
1999), and rectal involvement.
Medical Treatment
In this cohort, 185 patients (79.7%) received any drugs
(antibiotics, steroids, immunosuppresants, and anti-TNFs)
(Tables 2 and 3). Of the patients with simple fistulas (51),
41.2% underwent no treatment6 or solely surgery.15 In 15 patients
(29.4%), the treatment included drugs solely (Table 2), and in
the remaining 15 patients, (29.4%) the treatment involved both
drugs and surgery. Of the 30 patients (58.8%) with a simple fistula
who received drugs, only 1 type of drug was prescribed in
12 patients (40.0%) (Table 3).
In 26 patients (14.4%) suffering from a complex fistula, the
treatment involved solely surgery (11.6%) or no treatment (2.8%).
In 82 patients (45.3%), the treatment included solely drugs
(Table 2). Combination strategy including drugs and surgery
was given in 73 patients (40.3%). Of the 155 patients (85.6%)
with a complex fistula who received drugs, only 1 type of drug
was prescribed in 42 patients (27.1%) (Table 3).
In patients with simple fistulas, significantly more often
no drugs were prescribed (41.2%) compared with patients with
complex fistulas (14.4%) (P , 0.001). When drugs were the
only treatment administered, significantly more antibiotics
were prescribed in case of complex fistulas (P ¼ 0.047) and
significantly more steroids in case of simple fistulas (P ¼
0.027) (Table 2). Off all patients who received drugs with or
without additional surgery (79.7%), 54 patients (29.2%)
received only 1 type of drug (Table 3). The number of patients
receiving antibiotic therapy combined with one or more of the
other drugs was significantly higher when a complex fistula
was diagnosed compared with patients with a simple fistula
(65.5% versus 27.8%; P ¼ 0.004). Vice versa, steroids com-
bined with one or more drugs and maintenance anti-TNFs in
combination with one or more drugs were used more often by
patients with the diagnosis of simple fistula compared with
patients with a complex fistula (P , 0.001 and P ¼ 0.042,
respectively) (Table 3).
Overall, the most often prescribed drugs in both simple and
complex fistula were immunosuppressants (82.2%). If immuno-
suppressants were prescribed, steroids were part of the treatment
in simple fistulas in 13 patients (56.5%). In complex fistulas,
induction with anti-TNF was most often given concomitant with
FIGURE 1. Cumulative perianal fistula-free survival after diagnosis of
CD.
FIGURE 2. Flowchart showing the natural history of the patients with perianal fistulizing CD.
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immunosuppressants (52.7%). In 13 (43.3%) of patients with
simple fistulas and in 51 of patients with complex fistulas
(32.9%), anti-TNF maintenance therapy was prescribed. Almost
all of these patients received concomitant immunosuppressant
drugs (92.3% versus 88.2%).
Surgery
In total, 124 patients (53.4%) underwent surgery for
their fistulizing disease (Table 4). In patients with a simple
fistula, significantly more fistulectomies were performed than
in patients with a complex fistula (73.3% versus 42.6%; P ¼
0.006). Of patients with a complex fistula, 60 (63.8%) under-
went a fecal diversion compared with 8 (26.7%) in patients
with simple fistulas (P ¼ 0.001). In addition, significantly
more patients with a complex fistula underwent rectum ampu-
tation (25.5% versus 6.7%; P ¼ 0.037). Surgery was combined
with medical treatment in 15 patients (29.4%) with a simple
fistula and in 73 patients (40.3%) diagnosed with a complex
fistula (P ¼ 0.192).
Overall Effect of Treatment Strategies
The overall response to treatment rate was 83.7% (Fig. 2).
There was no significant difference between simple fistulas (93.3%)
and complex fistulas (81.3%) (P ¼ 0.068) regarding the response
rate. The overall remission rate was significantly higher in patients
with simple fistulas (88.2%) compared with complex fistulas
(64.6%) (P , 0.001), with a total overall remission rate of
69.8%. Fistula remission was achieved after a median duration of
27.0 months (range, 0–303.0 mo): in case of simple fistulas, the
median duration was 34.0 months (range, 0–187.0 mo) and after
27.0 months (range, 0–303.0 mo) in complex fistulas (P ¼ 0.785).
Initially healed fistulas recurred in 37.7%. Simple fistulas relapsed
less often compared with complex fistulas (26.7% versus 41.9%;
P ¼ 0.051). Only 37.0% of the complex fistulas were in remission
at the end of follow-up compared with 66.7% of the simple fistulas
(P , 0.001).
Response, Remission, and Relapse Rates Per
Treatment Strategy
No Treatment
In 6 patients (11.8%) with a simple fistula and 5 (2.8%)
patients with a complex fistula, no treatment was given (Fig. 2). In
4 of these patients with simple fistulas (66.7%) and 2 patients with
complex fistulas (40.0%), durable remission was achieved. The
time to remission was comparable between patients with a simple
fistula (40.0 mo [range, 12.0–187.0 mo] versus 37.5 mo [range,
3.0–72.0 mo]; P ¼ 1.000).
Drugs Only
The overall response in this group was 72.2%, with no
difference between simple and complex fistulas (P¼ 0.222) (Fig. 2).
The remission rate after an initial response to the medication was
64.3% without a significant difference between simple and complex
fistulas (P ¼ 0.121). Immunosuppressants, anti-TNF therapy, or the
TABLE 2. Drugs Prescribed in Patients Who Received







Pn ¼ 97 n ¼ 15 n ¼ 82
Drugs only
Antibiotics 51 (52.6) 4 (26.7) 47 (57.3) 0.047
Steroids 27 (27.8) 8 (53.3) 19 (23.2) 0.027
Immunosuppressants 82 (84.5) 13 (86.7) 69 (84.1) 1.000
Induction with anti-
TNFs
55 (56.7) 9 (60.0) 46 (56.1) 1.000
Maintenance therapy
anti-TNFs
36 (37.1) 8 (53.3) 28 (34.1) 0.244
TABLE 3. Drugs Prescribed for Simple and Complex
Fistulas







Pn ¼ 54 n ¼ 12 n ¼ 42
Antibiotics 8 (14.8) 2 (16.7) 6 (14.3) 1.000
Steroids 9 (16.7) 3 (25.0) 6 (14.3) 0.399
Immunosuppressants 34 (63.0) 7 (58.3) 27 (64.3) 0.744
Induction with anti-
TNFs
3 (5.5) 0 (0.0) 3 (7.1) 1.000
Maintenance therapy
anti-TNFs
0 (0.0) 0 (0.0) 0 (0.0) NA
More than 2 Types of Drugs n ¼ 131 n ¼ 18 n ¼ 113 P
Antibiotics 79 (60.3) 5 (27.8) 74 (65.5) 0.004
Steroids 54 (41.2) 15 (83.3) 39 (34.5) ,0.001
Immunosuppressants 118 (90.1) 16 (88.9) 102 (90.3) 1.000
Induction with anti-TNFs 90 (68.7) 14 (77.8) 76 (67.3) 0.427
Maintenance therapy
anti-TNFs
64 (48.9) 13 (72.2) 51 (45.1) 0.042
Total n ¼ 185 n ¼ 30 n ¼ 155 P
Antibiotics 87 (47.0) 7 (23.3) 80 (51.6) 0.005
Steroids 63 (34.1) 18 (60.0) 45 (29.0) 0.002
Immunosuppressants 152 (82.2) 23 (76.7) 129 (83.2) 0.435
Induction with anti-TNFs 93 (50.3) 14 (46.7) 79 (51.0) 0.694
Maintenance therapy anti-
TNFs
64 (34.6) 13 (43.3) 51 (32.9) 0.298
Overview of all patients who received drugs (n ¼ 185) with or without additional surgery
divided in patients who received one type of drug (n ¼ 54) and patients who received 2 or
more types of drugs (n ¼ 131).
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combination of both somewhere in the disease course of patients
with simple fistula did not improve remission rates compared with
patients who did not receive one of these drugs or the combination
of the both (P ¼ 1.000, P ¼ 0.525, and P ¼ 0.569, respectively).
Similar results were seen for patients with complex perianal fistulas
treated with immunosuppressants (P ¼ 0.379), anti-TNF (P ¼
0.119), and the combination of the both (P ¼ 0.121). Overall, fistula
remission was achieved after a median duration of 43.0 months
(range, 5.0–101.0 mo) in simple fistulas and after 23.5 months
(range, 3.0–203.0 mo) in complex fistulas (P ¼ 0.254). The recur-
rence rate after an initial response and remission in simple fistulas
was 27.3% and 11.8% in complex fistulas (P ¼ 0.337) with an
overall relapse rate of 15.6%.
Surgery Only
Fistulas that were treated with surgery only had an overall
response rate of 91.7% (Fig. 2). Overall remission after an initial
response was 97.0%. Median time to remission was 13.0 months
(range, 0.0–137.0 mo) in case of simple fistulas and 24.5 months
(range, 1.0–264.0 mo) in case of complex fistulas (P ¼ 0.589). No
significant difference was found in relapse rate between simple
(14.3%) and complex (27.8%) fistulas (P ¼ 0.426) with an overall
recurrence of 21.9%.
Drugs and Surgery Combined
In 29.4% of the simple fistulas and 40.3% of the complex
fistulas, a multimodal treatment with medication and surgery was
necessary (Fig. 2). The overall response rate was 93.2% with no
difference between simple and complex fistulas (P ¼ 0.584). The
overall remission rate after an initial response was 86.6%. Fistulas
went more often in remission in case of a simple fistula (100.0%)
compared with complex fistulas (83.6%) (P¼ 0.202) after a median
duration of 48.0 months (range, 0.0–136.0 mo) versus 34.0 months
(range, 0.0–303.0 mo) (P ¼ 0.854). When remission was achieved
after initial response, the overall recurrence rate was 64.8%.
Remission Rates Per CD Localization
All patients with CD localized only perianal or in the whole
gastrointestinal tract had a complex fistula. These complex fistulas
healed in 69.2% when isolated perianal disease was present and in
all patients with involvement of the entire gastrointestinal tract.
Simple fistulas healed significantly more often when luminal CD
was present in both small intestine and colon compared with
complex fistulas (95.2% versus 62.2%; P ¼ 0.006). When luminal
CD was localized in the large bowel or ileocecal, no significant
difference in fistula closure was found between simple and com-
plex fistulas (P ¼ 0.130 and P ¼ 0.121). Involvement of the
rectum was not associated with a lower remission rate in both
simple and complex fistulas (P ¼ 0.321 and P ¼ 0.255).
DISCUSSION
In this large retrospective cohort of patients with CD
suffering from perianal fistula, we assessed the effect of different
treatment strategies including surgery on the healing of these
fistulas. Because of the long-term median follow-up of 10 years,
we were able not only to investigate the time to first remission, but
also the rate of relapse after a first remission. Remission rate of the
first episode of perianal fistulas of the 232 patients was 69.8%.
Overall simple fistulas were more likely to heal than complex
fistulas (88.2% versus 64.6%; P , 0.001) without a significant
difference in median duration to first fistula healing. These rates
are comparable with previous studies reporting remission rates of
66% to 68% with also a higher healing rate of simple fistulas
compared with complex fistulas. In addition, no significant differ-
ence in time to fistula remission between simple and complex
fistulas was observed.7,9 The overall recurrence after initial heal-
ing, including the whole range of applied strategies, was a disap-
pointing 37.7%. Only 37.0% of the complex fistulas were in
remission at the end of follow-up compared with 66.7% of the
simple fistulas (P , 0.001). In several population-based co-
horts,6,7,9 the overall recurrence rate of fistulas was about one-
third. A prospective study in patients with solely perianal fistulas
observed a recurrence rate of 44.4%,30 which was higher than the
37.7% in our cohort.
Active rectal disease is indicated as a risk factor for perianal
fistula; in our cohort, only the minority of the patients had active
rectal disease. Involvement of the rectum was not associated with
a lower remission rate in both simple and complex fistulas (P ¼
0.321 versus P ¼ 0.255). However, our cohort included more
patients than previous studies.6,7,12 Furthermore, in patients with
active rectal disease, the risk for developing perianal fistulas com-
pared with patients with sole involvement of the small intestine
was reported to be higher. Only a small proportion of our cohort
had luminal disease present in solely the small intestine (6.9%) or
only ileocecal involvement (15.1%). Most patients had involve-
ment of the colon (37.9%) or colon and small intestine (28.9%),
which is in agreement with the literature that 5.6% of our patients
presented with isolated perianal disease and most of our patients
had colonic involvement or small intestine plus colonic
disease.6,10,11
We showed that 2.6% of the perianal fistulas healed without
any form of treatment that is even less than the already very low
TABLE 4. Surgery for Simple and Complex Fistulas







Pn ¼ 124 n ¼ 30 n ¼ 94
Colectomy 63 (50.8) 11 (36.7) 52 (55.3) 0.094
Fistulectomy 62 (50.0) 22 (73.3) 40 (42.6) 0.006
Fecal diversion
(stoma)
68 (54.8) 8 (26.7) 60 (63.6) 0.001
Rectum amputation 26 (21.0) 2 (6.7) 24 (25.5) 0.037
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spontaneous healing rates of 6% to 13% known from 3 placebo-
controlled studies.21,31,32 Healing rates after treatment with drugs
only vary between 9% and 78%7,9; however, the lowest reported
healing rates did not include anti-TNF therapy, and the number of
patients in these studies treated solely with drugs was low. In
a recent published meta-analysis including 453 patients with
active perianal fistulizing CD, complete closure of the fistula
was observed in only 32.8% of the patients after anti-TNF therapy
alone.25 Combining different medical treatments resulted in our
cohort in twice as higher closure rates (64.3%), suggesting that
solely anti-TNF therapy is not the optimal treatment for perianal
fistulizing CD. Surgery only did lead to a remission rate of 3
quarters; however, the number of patients treated with surgery
only was small (15.5%).
Infliximab was available in our hospital from 1999, and
57.7% of the patients treated solely with drugs received at least 1
gift of anti-TNF, however, not leading to higher remission rates of
perianal fistulas compared with patients who did not receive
infliximab (P ¼ 1.000). Our negative infliximab results may be
influenced by the time to treatment. Furthermore, the addition of
ciprofloxacin to anti-TNF significantly increased the rate of
healed fistulas in the ADAFI trial.27 If this strategy fails to heal
the fistula, options are scarce. Therefore, it is desirable to start
treatment as soon as possible after ruling out the presence of
abscesses and preferably placement of noncutting setons to reduce
the risk of new perianal abscess formation.
Recently, Sandborn et al33 reported the results of the first
induction and maintenance trials of vedolizumab, an a4b7-integrin
antibody. Although the number of patients with fistulas in this trial
was quite low, vedolizumab every 8 weeks resulted in a significant
higher closure rate compared with placebo (P ¼ 0.03).33 A new
promising approach in perianal fistula in CD is cellular therapy with
mesenchymal stromal cells. In the past years, several reports on
clinical trials using mesenchymal stromal cells as a treatment for
perianal fistulizing CD have demonstrated that the local administra-
tion of mesenchymal stromal cells is safe and feasible, and some of
these studies have suggested a potential therapeutic effect.34–37
In conclusion, we demonstrated in this large cohort of 232
patients with fistulising CD that only one third of the patients with
complex perianal fistulas achieved a durable remission after
conventional treatment strategies. Simple fistulas were more
likely to heal than complex fistulas, and less of these healed
fistulas relapsed. However, more than 3 quarters of the patients
had complex perianal fistulas. Rectum involvement and anti-TNF
therapy was not associated with lower remission rates.
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